Group 1: Epidemic Overview - The recent outbreak of Chikungunya fever in southern China has led to nearly 3,000 new cases reported in just one week, primarily in Guangdong province, affecting over ten cities [1][3] - The majority of cases are concentrated in Foshan, accounting for 95% of the total cases in Guangdong, with no severe cases or deaths reported so far [3] Group 2: Government Response and Guidelines - The National Health Commission has released the "Chikungunya Fever Diagnosis and Treatment Plan (2025 Edition)," emphasizing that the disease is preventable, controllable, and treatable [3][6] - The plan incorporates traditional Chinese medicine (TCM) approaches, highlighting the role of TCM in alleviating symptoms and promoting recovery [6] Group 3: Company Initiatives in Diagnostics and Treatment - Several listed companies in the IVD (in vitro diagnostics) sector are actively developing testing products and treatment solutions for Chikungunya fever [4][5] - Shenzhen BGI Technology Co., Ltd. has introduced the T1+ gene sequencer, which can provide comprehensive genomic analysis within 6-8 hours, aiding in rapid response to the outbreak [4] - Wanfu Biology has developed multiple Chikungunya virus detection products, creating a closed-loop system for monitoring and diagnosis [4] Group 4: Traditional Chinese Medicine Applications - TCM is being utilized for symptomatic treatment of Chikungunya fever, with specific formulations recommended for managing symptoms like fever and joint pain [6][7] - Companies such as Guangdong Yifang Pharmaceutical and Step Long Pharmaceutical are producing traditional Chinese medicines that may assist in treating Chikungunya fever [7]

Core Viewpoint - A nationwide price governance action for traditional Chinese medicine (TCM) is being implemented across multiple provinces in China, addressing the issue of inflated prices and the pressure it places on medical insurance funds [2][9]. Price Governance Action - Provinces such as Guangxi, Liaoning, Heilongjiang, and Tianjin have announced price governance measures for TCM, with additional provinces like Ningxia, Inner Mongolia, Shanxi, Henan, Hebei, and Jilin also participating [2]. - The governance is a response to the significant price discrepancies and the pressure on medical insurance funds caused by high TCM prices [2][11]. Price Discrepancies - Notable TCM products, including An Gong Niu Huang Wan and Ban Lan Gen Granules, have been identified with price differences exceeding 100 times between various manufacturers [3][4]. - A study indicated that out of 93 high-priced TCM products, only 6 had prices close to their theoretical retail prices, highlighting widespread price inflation [3]. Factors Contributing to Price Differences - Price variations are attributed to differences in ingredients, dosage forms, quality standards, and insufficient market competition, leading to concentrated pricing power among certain products [7][11]. - For instance, the daily treatment cost of An Gong Niu Huang Wan can reach 1,898 yuan in Inner Mongolia, significantly higher than the lowest price available [4]. Regulatory Measures - The National Medical Insurance Administration has initiated measures to regulate high-priced TCM products, requiring provinces to verify and adjust prices by July 31 [9][10]. - Provinces have been instructed to impose penalties on companies that fail to comply with price adjustments, including procurement risk identification and potential suspension of product listings [10]. Impact on Pharmaceutical Companies - The price governance affects various pharmaceutical companies, including well-known listed firms such as Taiji Group and Yabao Pharmaceutical, which are now under scrutiny for their pricing practices [12]. - Companies are expected to adapt to a new pricing model based on cost and efficacy, as reliance on high pricing and marketing strategies may no longer be sustainable [13]. Benefits for Patients - The price governance is anticipated to reduce the financial burden on patients, particularly for commonly used medications for chronic diseases, promoting fairer drug pricing and usage [13]. - Increased price transparency is expected to help regulate prescription practices and reduce the misuse of high-priced medications [13].

来源：金融界 广誉远最新一期业绩显示，截至2025一季报，公司营业总收入4.17亿元、同比增长21.48%，归属净利润 6358.43万元，同比增长53.94%，扣非净利润6364.12万元，同比增长31.24%，流动比率2.158、速动比率 1.134、资产负债率31.11%。 天眼查商业履历信息显示，广誉远中药股份有限公司，成立于1996年，位于晋中市，是一家以从事医药 制造业为主的企业。企业注册资本48949.1141万人民币，实缴资本7150.9万人民币。公司法定代表人为 李晓军。 通过天眼查大数据分析，广誉远中药股份有限公司共对外投资了10家企业，参与招投标项目36次，专利 信息2条，此外企业还拥有行政许可3个。 金融界消息 截至2025年7月29日收盘，广誉远（600771）报收于21.53元，上涨3.46%，换手率3.05%， 成交量14.94万手，成交金额3.18亿元。 资金流向方面，今日主力资金净流入1595.58万元，占比成交额5.02%。其中，超大单净流入786.17万 元、占成交额2.47%，大单净流入809.41万元、占成交额2.55%，中单净流出流入528.53万元、占成交额 1. ...

Core Viewpoint - The issue of excessively high prices for traditional Chinese medicine (TCM) has not been resolved, as evidenced by recent government actions targeting price adjustments for numerous TCM products across various provinces [1][2][4]. Group 1: Price Governance Actions - The Guangxi Drug Procurement Service Platform announced a price adjustment for 169 high-priced TCMs, requiring companies to complete adjustments by July 30 [1]. - Multiple provinces, including Jilin, Henan, and Jiangsu, have initiated price governance for TCMs, with notable products like An Gong Niu Huang Wan and Ban Lan Gen Granules being included [2]. - Jilin Province identified 52 TCMs with significant price discrepancies, with price differences ranging from 10 to over 117 times the minimum daily cost [2][3]. Group 2: Price Discrepancies and Examples - The price of TCMs is significantly higher compared to chemical drugs, with some products showing price differences exceeding 100 times [2]. - For instance, the price of Yuan Hu Zhi Tong Pian from Chongqing Xieran Pharmaceutical Co. is 110 yuan, with a daily cost of 45.83 yuan, leading to a price difference of 117.51 times the minimum daily cost [2][3]. Group 3: Historical Context and Ongoing Issues - The problem of high TCM prices has been persistent, with a 2009 study indicating that out of 93 high-priced TCMs, only 6 had prices close to their theoretical retail prices [4]. - Factors contributing to high prices include an inadequate pricing mechanism, numerous distribution channels, and commercial bribery in the pharmaceutical sector [4]. Group 4: Regulatory Developments - The National Medical Insurance Administration has initiated ongoing price governance for TCMs, with 28 provinces improving their drug pricing rules [4][5]. - The governance focuses on "average daily treatment costs," with penalties for products exceeding set price thresholds [5]. Group 5: Market Adaptations and Future Strategies - TCM companies are adapting to regulatory changes by exploring new profit avenues outside traditional markets, such as health products and wellness items [8]. - Companies like Li Shizhen and Tong Ren Tang are launching health-oriented products, indicating a shift in focus towards future growth opportunities [8][9].

Core Viewpoint - Guangyuyuan, a "Chinese Time-Honored Brand," is focusing on growth as a fundamental objective, emphasizing the importance of maintaining a competitive edge through strategic product positioning and operational efficiency [7][8][9]. Company Strategy - The company has adopted the "1541" strategic framework to promote growth as a primary goal, launching the "Dragon and Phoenix Big Product" strategy centered around its core products, Gui Ling Ji and Ding Kun Dan [8][9]. - In 2024, Guangyuyuan opened 43 new agents, increasing its total terminal stores to 462, with Gui Ling Ji sales growing over 25% and Ding Kun Dan nearly 10% [8]. Financial Performance - In Q1 2025, Guangyuyuan reported revenue of 417 million yuan, a year-on-year increase of 21.48%, and a net profit of 63.58 million yuan, up 53.94% [8]. Market Outlook - The health policy in China is expected to drive the market for premium traditional Chinese medicine, projected to exceed 300 billion yuan by 2030, aligning with Guangyuyuan's dual attributes of "treatment necessity + consumption upgrade" [9]. Product Development - Guangyuyuan emphasizes the importance of product efficacy, adhering to traditional methods in the production of its medicines, which include strict selection standards for raw materials [11][12]. - The company is also engaged in innovative research and development in collaboration with institutions like the China Academy of Chinese Medical Sciences [12]. Marketing and Growth Strategy - Guangyuyuan is implementing a "Four Feet and Two Wings" marketing strategy to enhance its market position and aims to become a leader in the premium traditional Chinese medicine sector within three years [13][14]. - The company is focusing on a multi-dimensional approach to marketing, including partnerships with top media and consulting firms to enhance brand visibility and market penetration [14][15].

Group 1 - Kanghong Pharmaceutical received a drug registration certificate for Lifisig Eye Drops, approved for treating dry eye symptoms [1] - Kanghong Biotech, a wholly-owned subsidiary, received clinical trial approval for KH813 injection for metastatic non-squamous non-small cell lung cancer [1] - Kanghong Pharmaceutical was established in October 1996, focusing on drug and medical device research, production, and sales [1] Group 2 - Guoyuyuan's subsidiary received a government subsidy of 7.5521 million yuan, accounting for 10.14% of the company's audited net profit for 2024 [2] - Guoyuyuan was founded in November 1996, specializing in drug research, production, and sales [3] Group 3 - Haicheng Bonda's subsidiary signed a lease termination agreement, incurring a termination fee of 3.35 million USD [4] - Haicheng Bonda was established in December 2009, providing comprehensive modern logistics services [4] Group 4 - Hongxin Electronics' subsidiary signed contracts totaling 373 million yuan for computing power business [5] - Hongxin Electronics was founded in September 2003, focusing on FPC research, design, manufacturing, and sales [6] Group 5 - Tianbang Food reached a settlement agreement regarding a 1.214 billion yuan lawsuit, agreeing to repay 410 million yuan over 36 months [8] - Tianbang Food was established in September 1996, specializing in pig farming and pork processing [9] Group 6 - Daoshi Technology's controlling shareholder plans to reduce holdings by up to 1.97% of the company's shares [10] - Daoshi Technology was founded in September 2007, focusing on ceramic color glazes and related products [10] Group 7 - Jinpu Titanium is planning a major asset restructuring, leading to a stock suspension [10] - Jinpu Titanium was established in November 1989, specializing in titanium dioxide production and sales [11] Group 8 - Shenzhen Energy plans to invest 6.332 billion yuan in upgrading the Mawan Power Plant [12] - Shenzhen Energy was founded in August 1993, focusing on conventional and renewable energy development [13] Group 9 - Lihua Co. plans to reduce holdings by up to 3% of the company's shares [14] - Lihua Co. was established in June 1997, specializing in the breeding and sales of poultry [15] Group 10 - China Communications Construction Company plans to repurchase shares worth 500 million to 1 billion yuan [16] - China Communications Construction Company was founded in October 2006, focusing on infrastructure design and construction [17] Group 11 - Huatiankeji's subsidiary received a government subsidy of 80.6569 million yuan, accounting for 13.09% of the company's latest audited net profit [20] - Huatiankeji was established in December 2003, specializing in integrated circuit packaging and testing [21] Group 12 - Luxin Chuangtou plans to acquire shares in Hongke Electronics for a total of 9 million yuan [23] - Luxin Chuangtou was founded in November 1993, focusing on venture capital and industrial development [24] Group 13 - Feilong Co.'s controlling shareholder plans to reduce holdings by up to 563,250 shares [25] - Feilong Co. was established in January 2001, specializing in thermal management components for automotive and civil applications [26] Group 14 - Linglong Tire submitted an application for H-share listing on the Hong Kong Stock Exchange [27] - Linglong Tire was founded in June 1994, focusing on tire design, development, manufacturing, and sales [27] Group 15 - Saiwei Electronics plans to acquire 9.5% of its subsidiary's shares for up to 324 million yuan [28] - Saiwei Electronics was established in May 2008, focusing on MEMS chip development and semiconductor equipment [28] Group 16 - Suzhou Bank's major shareholder plans to increase holdings by no less than 400 million yuan [29] - Suzhou Bank was founded in December 2004, focusing on various banking services [29]

对当期损益的影响：广誉远中药股份有限公司（以下简称"公司"）控股 子公司西藏广誉远药业有限公司收到与收益相关的政府补助，将直接计入损益, 具体的会计处理以及对公司损益的影响最终以审计机构年度审计确认后的结果 为准。 一、获得补助的基本情况 2025 年 6 月 27 日，公司控股子公司西藏广誉远药业有限公司收到与收益相 关的政府补助 7,552,142.00 元，占公司 2024 年度经审计归属于上市公司股东净 利润的 10.14%。 二、补助的类型及其对上市公司的影响 证券代码：600771 证券简称：广誉远 编号：临 2025-013 广誉远中药股份有限公司 关于控股子公司收到政府补助的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 获得补助金额：7,552,142.00 元 公司按照《企业会计准则第 16 号——政府补助》的相关规定，确认上述事 项并划分补助的类型，所收到的政府补助与收益相关，将直接计入损益。上述政 府补助未经审计，具体的会计处理以及对公司损益的影响最终以审计机构年度审 计确认后的结 ...

Core Viewpoint - The company emphasizes the necessity for traditional brands to actively embrace transformation rather than relying solely on historical achievements [1][5]. Group 1: Company Strategy and Performance - The company reported total assets of 2.276 billion yuan and achieved operating revenue of 1.221 billion yuan with a net profit attributable to shareholders of 74 million yuan for the year ending December 31, 2024 [3]. - In Q1 2025, the company experienced a strong rebound, with operating revenue reaching 417 million yuan, a year-on-year increase of 21.48%, and a net profit of approximately 63.58 million yuan, up 53.94% year-on-year [3]. - The "1541" strategic framework focuses on building a high-quality traditional Chinese medicine (TCM) industry chain, including five major actions: ensuring raw material supply, production support, marketing transformation, innovative research and development, and digital upgrades [5]. Group 2: Market Challenges and Responses - The company faces challenges such as shrinking market share, profit compression due to medical insurance cost control, intensified competition from traditional channels, and the need for product innovation driven by consumer downgrade [5]. - The company has restructured its channel strategy by enhancing collaboration with top chain enterprises and expanding its network, adding 43 new agents and reaching a total of 462 retail stores in 2024 [5]. Group 3: Cultural and Brand Development - The company is committed to strengthening its cultural foundation and brand value, addressing key questions about its value system and driving forces during the shareholder meeting [6]. - Initiatives include establishing a heritage studio with scholars, conducting educational activities, and launching live broadcasts to enhance brand cultural influence [6]. - The company plans to restore historical sites and apply for recognition of its industrial heritage, aiming to showcase its rich cultural background and create a new historical experience area [6]. Group 4: Long-term Vision - The company is pursuing a long-term strategy to navigate industry cycles, focusing on strategic determination, innovative vitality, and cultural appeal to achieve its goal of becoming a flagship enterprise in TCM [7].

证券代码：600771 证券简称：广誉远 公告编号：2025-012 广誉远中药股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 其中，现场出席本次股东大会的股东及股东代表共 13 人，代表股份 74,991,867 股，占公司有表决权股份总数的 15.32%；参加网络投票的股东及股 东代表共 912 人，代表股份 9,734,784 股，占公司有效表决权股份总数的 1.99%。 (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由董事会召集，董事长李晓军主持，会议采取现场投票与网络投票 相结合的表决方式。会议的召集、召开及表决方式符合《公司法》、《公司章程》 及其他有关法律、法规的规定。 (五)公司董事、监事和董事会秘书的出席情况 1、公司在任董事6人，出席4人，董事季占璐因公务原因未能亲自出席本次会议； (一)股东大会召开的时间：2025 年 6 月 24 日 (二)股东大会召开的地点：山西省太原市小店区长 ...

北京海润天睿律师事务所 关于广誉远中药股份有限公司 2024 年年度股东大会的法律意见书 致:广誉远中药股份有限公司 北京海润天睿律师事务所(以下简称"本所")接受广誉远中药股份有限公 司(以下简称"公司")的委托,指派冯政律师、陈媛律师出席公司 2024 年年度 股东大会,并依据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人 民共和国证券法》(以下简称"《证券法》")、《上市公司股东会规则》等法律、法 规和规范性文件及《公司章程》的规定,就公司本次股东大会的召集、召开程序、 出席会议人员的资格、召集人资格、表决程序、表决结果等有关事宜出具本法律 意见书。 对本法律意见书的出具,本所律师特作如下声明: 1. 本所及经办律师依据《证券法》《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则》等规定及本法律意见书出具日以前已经 发生或者存在的事实,严格履行了法定职责，遵循了勤勉尽责和诚实信用原则, 进行了充分的核查验证,保证本法律意见所认定的事实真实、准确、完整,所发 表的结论性意见合法、准确,不存在虚假记载、误导性陈述或者重大遗漏，并承 担相应法律责任。 2. 本所律师仅就本 ...